{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:20:34Z","timestamp":1788268834940,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.7759\/cureus.115585","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:47:25Z","timestamp":1788266845000},"source":"Crossref","is-referenced-by-count":0,"title":["Multiple Myeloma and Renal Health: Navigating Selected Clinical Complexities"],"prefix":"10.7759","author":[{"given":"Azhar","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack L","family":"Moniot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsena","family":"Sumaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4236\/ojneph.2025.152023","article-title":"Renal failure due to multiple myeloma","volume":"15","author":"Shaik A","year":"2025","unstructured":"Shaik A, Oroszi T. Renal failure due to multiple myeloma. Open J Nephrol. 2025, 15:228-246. 10.4236\/ojneph.2025.152023","journal-title":"Open J Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk NJ","year":"2021","unstructured":"van de Donk NJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021, 397:410-427. 10.1016\/S0140-6736(21)00135-5","journal-title":"Lancet"},{"key":"ref3","unstructured":"American Cancer Society. Key Statistics About Multiple Myeloma. (2026). Accessed: January 13, 2026: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html."},{"key":"ref4","unstructured":"International Myeloma Working Group (IMWG) criteria for the diagnosis of multiple myeloma. (2014). Accessed. August 9, 2026: https:\/\/www.myeloma.org\/international-myeloma-working-group-imwg-criteria-diagnosis-multiple-myeloma."},{"key":"ref5","unstructured":"Durie GB. What are CRAB and pre-CRAB criteria in myeloma diagnosis, and how do they affect treatment decision-making?. (2024). Accessed:  April 16, 2024: https:\/\/www.myeloma.org\/videos\/are-crab-pre-crab-criteria-myeloma-diagnosis-how-do-they-affect-treatment-decision-making."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos MA","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, et al.. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014, 25:195-200. 10.1093\/annonc\/mdt483","journal-title":"Ann Oncol"},{"key":"ref7","unstructured":"Kidney disease in multiple myeloma and other monoclonal gammopathies. etiology and evaluation. (2025). Accessed: June 5, 2026: https:\/\/www.uptodate.com\/contents\/kidney-disease-in-multiple-myeloma-and-other-monoclonal-gammopathies-etiology-and-e...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2012.37","article-title":"The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies","volume":"2","author":"Kalff A","year":"2012","unstructured":"Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012, 2:e89. 10.1038\/bcj.2012.37","journal-title":"Blood Cancer J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar SV","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022, 97:1086-1107. 10.1002\/ajh.26590","journal-title":"Am J Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard F","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, et al.. Multiple myeloma. Nat Rev Dis Primers. 2024, 10:45. 10.1038\/s41572-024-00529-7","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/864058","article-title":"The genetic architecture of multiple myeloma","volume":"2014","author":"Prideaux SM","year":"2014","unstructured":"Prideaux SM, Conway O'Brien E, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014, 2014:864058. 10.1155\/2014\/864058","journal-title":"Adv Hematol"},{"key":"ref12","article-title":"Monoclonal Gammopathy of Undetermined Significance","author":"Kaseb H","year":"2026","unstructured":"Kaseb H, Annamaraju P, Babiker HM. Monoclonal Gammopathy of Undetermined Significance. StatPearls Publishing, Treasure Island, FL; 2026."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2022.00095","article-title":"A personalized molecular approach in multiple myeloma: the possible use of RAF\/RAS\/MEK\/ERK and BCL-2 inhibitors","volume":"3","author":"Raimondi V","year":"2022","unstructured":"Raimondi V, Iannozzi NT, Burroughs-Garc\u00eca J, Toscani D, Storti P, Giuliani N. A personalized molecular approach in multiple myeloma: the possible use of RAF\/RAS\/MEK\/ERK and BCL-2 inhibitors. Explor Target Antitumor Ther. 2022, 3:463-479. 10.37349\/etat.2022.00095","journal-title":"Explor Target Antitumor Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101177","article-title":"MYC alterations in multiple myeloma: genetic insights and prognostic impact","volume":"66","author":"Crist\u00f3bal-Vargas S","year":"2025","unstructured":"Crist\u00f3bal-Vargas S, Cuadrado M, Guti\u00e9rrez NC. MYC alterations in multiple myeloma: genetic insights and prognostic impact. Neoplasia. 2025, 66:101177. 10.1016\/j.neo.2025.101177","journal-title":"Neoplasia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar SV","year":"2015","unstructured":"Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015, 125:3069-3075. 10.1182\/blood-2014-09-568899","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, et al.. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020, 10:102. 10.1038\/s41408-020-00366-3","journal-title":"Blood Cancer J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215148","article-title":"Inflammatory bone marrow mesenchymal stem cells in multiple myeloma: transcriptional signature and in vitro modeling","volume":"15","author":"Wang L","year":"2023","unstructured":"Wang L, Yi W, Ma L, Lecea E, Hazlehurst LA, Adjeroh DA, Hu G. Inflammatory bone marrow mesenchymal stem cells in multiple myeloma: transcriptional signature and in vitro modeling. Cancers (Basel). 2023, 15:5148. 10.3390\/cancers15215148","journal-title":"Cancers (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v15.i5.421","article-title":"Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression","volume":"15","author":"Garc\u00eda-S\u00e1nchez D","year":"2023","unstructured":"Garc\u00eda-S\u00e1nchez D, Gonz\u00e1lez-Gonz\u00e1lez A, Alfonso-Fern\u00e1ndez A, Del Dujo-Guti\u00e9rrez M, P\u00e9rez-Campo FM. Communication between bone marrow mesenchymal stem cells and multiple myeloma cells: impact on disease progression. World J Stem Cells. 2023, 15:421-437. 10.4252\/wjsc.v15.i5.421","journal-title":"World J Stem Cells"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2022.110","article-title":"Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions","volume":"9","author":"Moscvin M","year":"2023","unstructured":"Moscvin M, Evans B, Bianchi G. Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions. J Cancer Metastasis Treat. 2023, 9:17. 10.20517\/2394-4722.2022.110","journal-title":"J Cancer Metastasis Treat"},{"key":"ref20","article-title":"Multiple Myeloma","author":"Albagoush SA","year":"2023","unstructured":"Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22585","article-title":"Multiple myeloma and renal failure: mechanisms, diagnosis, and management","volume":"14","author":"Kundu S","year":"2022","unstructured":"Kundu S, Jha SB, Rivera AP, et al.. Multiple myeloma and renal failure: mechanisms, diagnosis, and management. Cureus. 2022, 14:e22585. 10.7759\/cureus.22585","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.02.026","article-title":"The proximal tubule toxicity of immunoglobulin light chains","volume":"6","author":"Sirac C","year":"2021","unstructured":"Sirac C, Batuman V, Sanders PW. The proximal tubule toxicity of immunoglobulin light chains. Kidney Int Rep. 2021, 6:1225-1231. 10.1016\/j.ekir.2021.02.026","journal-title":"Kidney Int Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2019.100159","article-title":"Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma","volume":"21","author":"Buege MJ","year":"2019","unstructured":"Buege MJ, Do B, Lee HC, et al.. Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. Cancer Treat Res Commun. 2019, 21:100159. 10.1016\/j.ctarc.2019.100159","journal-title":"Cancer Treat Res Commun"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/ar2168","article-title":"Multiple myeloma\/hypercalcemia","volume":"9","author":"Oyajobi BO","year":"2007","unstructured":"Oyajobi BO. Multiple myeloma\/hypercalcemia. Arthritis Res Ther. 2007, 9:S4. 10.1186\/ar2168","journal-title":"Arthritis Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","volume":"25","author":"Raje NS","year":"2019","unstructured":"Raje NS, Bhatta S, Terpos E. Role of the RANK\/RANKL pathway in multiple myeloma. Clin Cancer Res. 2019, 25:12-20. 10.1158\/1078-0432.CCR-18-1537","journal-title":"Clin Cancer Res"},{"key":"ref26","article-title":"Nephrocalcinosis","author":"Vaidya SR","year":"2026","unstructured":"Vaidya SR, Yarrarapu SNS, Aeddula NR. Nephrocalcinosis. StatPearls Publishing, Treasure Island, FL; 2026."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030420","article-title":"Randall-type monoclonal immunoglobulin deposition disease: new insights into the pathogenesis, diagnosis and management","volume":"11","author":"Cohen C","year":"2021","unstructured":"Cohen C, Joly F, Sibille A, et al.. Randall-type monoclonal immunoglobulin deposition disease: new insights into the pathogenesis, diagnosis and management. Diagnostics (Basel). 2021, 11:420. 10.3390\/diagnostics11030420","journal-title":"Diagnostics (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05901-1","article-title":"Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies","volume":"104","author":"Cassano RC","year":"2025","unstructured":"Cassano RC, Muchtar E, Magen H, et al.. Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies. Ann Hematol. 2025, 104:1-10. 10.1007\/s00277-024-05901-1","journal-title":"Ann Hematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1271482","article-title":"Renal monoclonal immunoglobulin deposition disease: the disease spectrum","volume":"12","author":"Lin J","year":"2001","unstructured":"Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol. 2001, 12:1482-1492. 10.1681\/ASN.V1271482","journal-title":"J Am Soc Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly F","year":"2019","unstructured":"Joly F, Cohen C, Javaugue V, et al.. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019, 133:576-587. 10.1182\/blood-2018-09-872028","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:538-548. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar SV","year":"2016","unstructured":"Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016, 91:719-734. 10.1002\/ajh.24402","journal-title":"Am J Hematol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle RA","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009, 23:3-9. 10.1038\/leu.2008.291","journal-title":"Leukemia"},{"key":"ref34","unstructured":"NCCN Guidelines. Multiple Myeloma. (2026). Accessed: June 5, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa127","article-title":"Preventive strategies for acute kidney injury in cancer patients","volume":"14","author":"Cosmai L","year":"2021","unstructured":"Cosmai L, Porta C, Foramitti M, Perrone V, Mollica L, Gallieni M, Capasso G. Preventive strategies for acute kidney injury in cancer patients. Clin Kidney J. 2021, 14:70-83. 10.1093\/ckj\/sfaa127","journal-title":"Clin Kidney J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos MA","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, et al.. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016, 34:1544-1557. 10.1200\/JCO.2015.65.0044","journal-title":"J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma","volume":"1","author":"Yadav P","year":"2016","unstructured":"Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel). 2016, 1:241-257. 10.1159\/000442511","journal-title":"Kidney Dis (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2013.79","article-title":"Risk factors for chronic kidney disease: an update","volume":"3","author":"Kazancio\u011flu R","year":"2013","unstructured":"Kazancio\u011flu R. Risk factors for chronic kidney disease: an update. Kidney Int Suppl (2011). 2013, 3:368-371. 10.1038\/kisup.2013.79","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref39","article-title":"Long hemodialysis treatment with high cut-off membranes in patients with acute kidney injury secondary to multiple myeloma: case presentations","volume":"8","author":"Markovska SZ","year":"2024","unstructured":"Markovska SZ, Bushljetik RI, Severova G, et al.. Long hemodialysis treatment with high cut-off membranes in patients with acute kidney injury secondary to multiple myeloma: case presentations. Clin Case Rep Int. 2024, 8:1699.","journal-title":"Clin Case Rep Int"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1024133","article-title":"High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury","volume":"12","author":"Xing Y","year":"2022","unstructured":"Xing Y, Yan J, Yu Z, et al.. High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury. Front Oncol. 2022, 12:1024133. 10.3389\/fonc.2022.1024133","journal-title":"Front Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000150","article-title":"High-cutoff hemodialysis therapy for patients with light chain cast nephropathy and AKI requiring dialysis: CON","volume":"4","author":"Karakala N","year":"2023","unstructured":"Karakala N, Juncos LA. High-cutoff hemodialysis therapy for patients with light chain cast nephropathy and AKI requiring dialysis: CON. Kidney360. 2023, 4:1024-1026. 10.34067\/KID.0000000000000150","journal-title":"Kidney360"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000149","article-title":"High-cutoff hemodialysis therapy for patients with light chain cast nephropathy and AKI requiring dialysis: commentary","volume":"4","author":"Cosmai L","year":"2023","unstructured":"Cosmai L, Gallieni M. High-cutoff hemodialysis therapy for patients with light chain cast nephropathy and AKI requiring dialysis: commentary. Kidney360. 2023, 4:1027-1029. 10.34067\/KID.0000000000000149","journal-title":"Kidney360"},{"key":"ref43","unstructured":"IMWG recommendations on managing multiple myeloma-related renal impairment. (2022). Accessed. June 5, 2026: https:\/\/www.myeloma.org\/resource-library\/imwg-recommendations-managing-multiple-myeloma-related-renal-impairment."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2705","article-title":"Lenalidomide use in multiple myeloma (Review)","volume":"20","author":"Zhang CW","year":"2024","unstructured":"Zhang CW, Wang YN, Ge XL. Lenalidomide use in multiple myeloma (Review). Mol Clin Oncol. 2024, 20:7. 10.3892\/mco.2023.2705","journal-title":"Mol Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503951-multiple-myeloma-and-renal-health-navigating-selected-clinical-complexities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:47:27Z","timestamp":1788266847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503951-multiple-myeloma-and-renal-health-navigating-selected-clinical-complexities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.115585","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}